MEDICILON

以技术为支柱
以效率为引擎

2025 4 FDA

AI NAMs AI

NAMs NAMs

NAMs AI

NAMs (*in vitro*) (*ex vivo*) (*in silico*)

- 3D Organ-on-Chip MPS Organoid
- PBPK QSP QST

/

→ NAMs

AI

Target-to-hit Hit-to-lead Lead-to-PCC

- GPCRs
-
-
-

- CellTiter Glo/LDH/MTT/CCK-8
- / /
- HepG2, HUVEC, HEK293, SH-SY5Y
- PBMC

- ROS
-

- hERG
- Nav1.5 Cav1.2
- iPSC -2D/3D

-
- HepG2/ - Seahorse
-
- ROS

- MDCK HEK293 Vero HK-2
-

- Mini-AMES
- AMES
- AMES
-
-

- 12 43
- -CTG LDH
- -RNAseq
-

- /PBMC
- T /
- B /
- (MLR)
- PBMC-PDXO

- 3T3

-

-
-
-












| mM | 2D 24h | 2D 48h | 2D 72h |
|---|---|---|---|
| IC50 | 20.86 | 20.68 | 15.22 |




| D 96 | D 144h | D 192h | D 264h |
|---|---|---|---|
| 1.57 | 1.34 | 1.30 | 1.47 |

CDE 2020 IND

CRA


5000
4000
3000
2000
1000
0

| | | |
|---|---|---|
| | | |
| | | |
| | | |



:

- 0.1×106 cells/
- 0.2×106 cells /
- 0.4×106 cells /
- PBMC 4




:

→LDH PBMC

→ PBMCs

PBMC PDXO







PBPK

PBPK

ADME

PK

- △ PBPK
- △ PK

PK

NAMs NAMs FDA


上海美迪西生物医药股份有限公司